Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Insulin; related peptides
Reexamination Certificate
1999-02-23
2001-03-06
Moezie, F. T. (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Insulin; related peptides
C435S069400, C435S173300, C530S326000, C514S002600, C514S003100, C514S012200
Reexamination Certificate
active
06197926
ABSTRACT:
TECHNICAL FIELD
The present invention relates generally to peptide analogues of insulin, and more specifically to methods for treating diabetes using peptide analogues derived from residues 9-23 of human insulin B chain.
BACKGROUND OF THE INVENTION
Insulin dependent diabetes mellitus (IDDM) is an organ specific autoimmune disease affecting close to a million people in different age groups in the United States. The disease is characterized by extensive destruction of the insulin producing beta cells in the pancreatic islets and dysregulation of glucose metabolism leading to frank diabetes. The defining feature of IIDM is the lymphocytic infiltration of the islets. Among the invading cells, T cells appear to be one of the major mediators of autoimmune destruction.
Type I diabetes is further characterized by increased levels of antibodies to various islet associated antigens, including insulin, GAD65, GAD67 and ICA512. These antibodies can be detected much before frank disease, and an immune response to such antigens can be used as a predictor for impending diabetes in patients with susceptible genetic (HLA) haplotypes.
Currently, patients are dependent on insulin injections to maintain normoglycemia. Insulin is a polypeptide hormone consisting of two disulfide-linked chains, an A chain consisting of 21 amino acid residues and a B chain of 30 residues. While administration of insulin provides significant benefits to patients suffering from diabetes, the short serum half-life of insulin creates difficulties for maintaining proper dosage. The use of insulin also can result in a variety of hypoglycemic side-effects and the generation of neutralizing antibodies.
In view of the problems associated with existing treatments of diabetes, there is a compelling need for improved treatments that are more effective and are not associated with such disadvantages. The present invention exploits the use of peptide analogues which antagonize a T cell response to insulin to effectively treat diabetes, while further providing other related advantages.
SUMMARY OF THE INVENTION
The present invention provides compounds and methods for treating and preventing diabetes. Within certain aspects, the present invention provides peptide analogues comprising residues 9 to 23 of human insulin B chain (SEQ ID NO:2). wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to substitutions at between 1 and 4 amino acid positions. Such substitutions may be made at one or more residues selected from the group consisting of residues 12, 13, 15 and 16, with or without additional substitutions at other residues. Within certain preferred embodiments, such substitutions may occur at two or three amino acid residues within residues 9 to 23 of insulin B chain. Substitutions may also occur at residue 19. Substitutions are preferably non-conservative, and analogues wherein residue 12, 13, 15, 16 and/or 19 are altered (to, for example, alanine) are preferred. Analogues further comprising residue 24 of insulin B chain are also preferred. In certain other embodiments, the peptide analogues comprise no more than 18 residues, no more than 16 residues or no more than 15 residues of human insulin B chain.
Within further embodiments, the peptide analogues consist essentially of residues 9 to 23 or 9 to 24 of human insulin B chain (SEQ ID NO:2), wherein the peptide analogue differs in sequence from native human insulin B chain residues 9 to 23 due to substitutions at between 1 and 4 amino acid positions, and wherein at least one substitution occurs at a residue selected from the group consisting of residues 12, 13, 15 and 16.
Within further aspects, pharmaceutical compositions are provided, comprising a peptide analogue as described above in combination with a physiologically acceptable carrier or diluent.
The present invention further provides methods for treating and/or inhibiting the development of diabetes comprising administering to a patient a therapeutically effective amount of a pharmaceutical composition as described above.
These and other aspects of the invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth below which describe in more detail certain procedures or compositions. These references are incorporated herein by reference in their entirety as if each were individually noted for incorporation.
REFERENCES:
patent: 5008241 (1991-04-01), Markussen et al.
patent: 5559094 (1996-09-01), Brems et al.
patent: 5594100 (1997-01-01), Wegmann
patent: 5618913 (1997-04-01), Brange et al.
patent: WO 96/04307 (1996-02-01), None
patent: WO 97/02043 (1997-01-01), None
Daniel and Wegmann, “Intranasal Administration of Insulin Peptide B: 9-23 Protects NOD Mice from Diabetes,”Annals Of the New York Academy of Sciences 778:371-372, 1996.
Daniel and Wegmann, “Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23),”Proc. Natl. Acad. Sci. USA 93:956-960, 1996.
Gattner et al., “The Preparation of Two Mutant Forms of Human Insulin, Containing Leucine in Position B24 or B25, by Enzyme-Assisted Synthesis,”Hoppe-Seyler's Z. Physiol. Chem. Bd. 361:1135-1138, 1980.
Jonczyk et al., “Preparation and Biological Properties of [LeuB24, LeuB25]Human Insulin,”Hoppe Seyler's Z. Physiol. Chem. Bd. 362:557-561, 1981.
Katsoyannis et al., “Insulin Peptides. XIX. The Synthesis of Two Nonapeptide Derivatives Related to the N Terminus of the B Chain of Insulin from Various Species (Positions 1-9),”Journal of the American Chemical Society 93(22): 5862-5866, 1971.
Kung et al., “Synthesis Of The Peptide Fragments Of The B-Chain Of Insulin,”Scientia Sinica XV(2): 221-230, 1966.
Lenz et al., “Semisynthetic Des-(B27-B30)-insulins with Modified B26-Tyrosine,”Biol. Chem. Hoppe-Seyler 372:495-504, 1991.
Leyer et al., “The role of the C-terminus of the insulin B-chain in modulating structural and functional properties of the hormone,”Int. J. Peptide Protein Res. 46:397-407, 1995.
Losse et al., “Synthese Eines Kondensationsfähigen Insulin-B15-20-Hexapeptidderivates,”Tetrahedron 33:1817-1819, 1977.
Riemen et al., “Preparation of Semisynthetic Insulin Analogs from Bis(tert-butyloxycarbonyl)-desoctapeptide-insulin Phenylhydrazide: Importance of the Aromatic Region B24-B26,”Biochemistry 22:1507-1515, 1983.
Schwartz and Katsoyannis, “Insulin Peptides. Part XXIII. The Synthesis of a Hexadecapeptide Derivative Related to the B Chain of Human Insulin,”J. Chem. Soc. Perkin I:2890-2894, 1973.
Schwartz and Katsoyannis, “Synthesis of Des(tetrapeptide B1-4) and Des(pentapeptide B1-5) Human Insulins. Two Biologically Active Analogues,”Biochemistry17(21): 4550-4556, 1978.
Schwartz et al., “[12-Asparagine-B] Human Insulin: An Analogue with Modification in the Hydrophobic Core of Insulin,”Int. J. Peptide Protein Res. 17:243-255, 1981.
Svoboda et al., “Semisynthetic Insulin Analogues Modified in Positions B24, B25, and B29,”Biol. Chem. Hoppe-Seyler 375:373-378, 1994.
Toyota et al., “Effects of Hexapeptide, a Compound Analogous to Insulin B Chain Fragment B-21-26(DP-432) on the Glucose Uptake in to the Perfused Hing Limb of Rats,”Hormone and Metabolic Research 10:17-20, 1978.
Wang et al., “Insulin Analogues with Modifications in the &bgr;-Turn of the B-Chain,”Journal of Protein Chemistry 10(3): 313-324, 1991.
Weitzel et al., “Structure and Activity of Insulin, XVI[1-6]. Semisyntheses of Desheptapeptide-(B24-30)- up to Destripeptide-(B28-30)-Insulin with Lysine or Alanine in Place of Arginine in Position B22: Influence on the Three-Step-Increase of Activity in Positions B24-26 (Phe-Phe-Tyr),”Hoppe Seyler's Z. Physiol. Chem. Bd. 359:945-958 1978.
Polanski et al., “Oral Administration of the Immunodominant B-chain of Insulin Reduces Diabetes in a Co-transfer Model of Diabetes in the NOD Mouse and is Associated with a Switch from Th1 to Th2 Cytokines,”Journal of Autoimmunity 10(4): 339-346, 1997.
Conlon Paul J.
Gaur Amitabh
Ling Nicholas
Moezie F. T.
Neurocrine Biosciences
Seed Intellectual Property Law Group PLLC
LandOfFree
Methods for treatment of diabetes using peptide analogues of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of diabetes using peptide analogues of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of diabetes using peptide analogues of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2472683